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Abstract
Introduction—Prophylaxis is considered the optimal treatment for persons with moderate to 
severe haemophilia (factor activity between 1–5% of normal and <1% of normal respectively) in 
countries where safe factor concentrates are available and economically feasible. Historically, 
prophylactic treatment has not been well studied in the haemophilia B (HB) population due to 
difficulties in obtaining a sufficiently large sample.
Aim—This study examines the prevalence of prophylaxis use among a robust sample of persons 
with HB in the United States and its association with specific demographic and clinical 
characteristics.
Methods—Using data collected between 1998 and 2011 for the Centers for Disease Control and 
Prevention’s Universal Data Collection project, we analysed data on 2428 males with moderate to 
severe HB aged 2–79 years who were seen at 135 federally funded haemophilia treatment centres.
Results—Prevalence of prophylactic treatment in our sample was 35% among children and youth 
(ages 2–19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was 
significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-
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infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. 
Health care coverage was vital, although type of coverage did not appear to influence access.
Conclusions—Our analysis confirms previous reports of lower prevalence of prophylaxis use 
among individuals with HB compared to those with haemophilia A and adds to the body of 
knowledge regarding treatment patterns among a historically understudied population.
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1 | INTRODUCTION AND BACKGROUND
Prophylaxis, the regularly scheduled infusion of factor concentrate to prevent bleeding, is 
considered the optimal treatment for all persons with severe haemophilia.1,2 By raising 
factor VIII (FVIII) or factor IX (FIX) activity levels above one percent of normal, 
prophylaxis reduces spontaneous bleeding and subsequent joint arthropathy, and is 
associated with improved physical and psychosocial outcomes.3–6 Routine use of 
prophylaxis beginning early in life was pioneered in northern Europe in the 1950s; its 
effectiveness among individuals with severe haemophilia A (HA) was confirmed in two 
landmark randomized clinical trials published in 2007 (US) and 2011 (Italy).7,8 Both studies 
demonstrated the ability of preventative therapy to reduce joint damage compared to factor 
administered after bleeding. The impact of the US study was evident in a 2010 survey of US 
haemophilia treatment centres (HTCs) in which 66% of severe HA patients received some 
form of prophylaxis, a 10% increase from 2008.9
Previous reports suggest that persons with HA are more likely than those with haemophilia 
B (HB) to use prophylaxis and have revealed variations in prophylaxis use among US 
HTCs.9,10 Possible explanations for lower prophylaxis use in HB include the greater 
prevalence of mild and moderate HB patients compared to those with HA and a less severe 
clinical phenotype.11,12 Few studies have focused exclusively on prophylaxis in HB because 
of the difficulty of obtaining a robust sample; therefore much of our knowledge regarding 
prophylaxis use is based on the HA population. The question of whether persons with severe 
HB should be placed on a prophylactic regimen as frequently as those with severe HA 
remains a subject of debate among haemophilia care providers.13–18
Using a large national sample, this study (i) examines the prevalence of prophylaxis use 
among individuals with moderate and severe HB and (ii) investigates the association of 
prophylaxis use with clinical and demographic factors similar to those previously reported in 
the HA population.
2 | METHODS
The Universal Data Collection (UDC) surveillance project was conducted by the CDC and 
135 federally funded HTCs in the US to collect a uniform set of clinical outcomes data on 
persons who received comprehensive care at these centres. More than 18 000 males, 
representing 85% of persons with haemophilia receiving care at HTCs, were enrolled from 
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1998 to 2011.10,11 From a study population of 3825 males aged 2–79 years diagnosed with 
HB, we excluded individuals with mild disease (n=943) and clinical or treatment 
characteristics having the potential to affect weight status or the ability to treat 
prophylactically, including a diagnosis of HIV or symptomatic liver disease (n=704); 
inhibitor titre ≥5 Bethesda units (n=21); and immune tolerance therapy at the time of the 
visit (n=6). Individuals using intermittent prophylaxis (prophylaxis not expected to continue 
for an indefinite period of time) were excluded (n=6), as were those with incomplete height 
and weight data at the time of the most recent UDC visit (n=112). The study sample includes 
2428 persons with moderate or severe HB.
Demographic and clinical data were collected from consenting UDC participants by HTC 
staff members during UDC visits using standardized data collection instruments. The 
registration form (completed once at enrollment) recorded month and year of birth, gender, 
race/ethnicity, factor deficiency, diagnosis and baseline factor activity; the annual visit form 
(completed at subsequent visits) collected visit date, current height, weight, insurance 
coverage, home infusion status, person performing the infusion (self, family member or 
medical care provider) and treatment regimen (episodic or prophylaxis). Data from the most 
recent UDC visit were used in the analyses.
2.1 | Definition of variables
CDC guidelines, including gender-specific growth charts, were used to define categories of 
overweight and obesity based on measured height and weight. Above-normal body mass 
index (BMI) in adults was defined as BMI≥25.0; in children and youth 2–19 years, as BMI-
for-age ≥95th percentile. Obesity was defined as BMI≥30 for adults and as BMI-for-age 
≥97th percentile for those <20 years. Participants with baseline factor activity between 1–5% 
of normal levels were considered to have moderate haemophilia, and those with <1%, severe 
haemophilia.1 Participants were grouped into five age categories: (i) 2–5 years; (ii) 6–11 
years; (iii) 12–19 years; (iv) 20–39 years; and (v) 40 years or older. Treatment type was 
classified as episodic if the patient received products only in response to bleeding 
complications since the last annual clinic visit. Individuals were considered to be on a 
prophylactic regimen if they received treatment products on a regular schedule expected to 
continue indefinitely in order to prevent any and all bleeding. We examined four categories 
of insurance coverage: (i) no insurance; (ii) commercial insurance; (iii) publicly funded 
insurance (Medicaid, CHIP, Medicare, Tricare and state programmes for chronically ill/
disabled persons); and (iv) all other forms of insurance. Persons with any form of 
commercial or public health care coverage were considered to have health insurance. For 
analysis of geographic variation, the sample was divided into four U.S. Census Bureau 
geographic regions: West, Midwest, Northeast and South. Racial/ethnic groups included 
non-Hispanic White, African-American (non-Hispanic black), Hispanic and Other.
2.2 | Statistical methods
We conducted descriptive and bivariate analyses followed by a series of multiple logistic 
regression models to assess the independent associations of prophylaxis use with 
demographic and clinical characteristics.
Ullman et al. Page 3
Haemophilia. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Percentages of age, race/ethnicity, health insurance status, BMI, severity, self-infusion status 
and geographic location were calculated to describe demographic and clinical 
characteristics. The prevalence of prophylaxis use for each level of these variables was 
calculated. Bivariate analyses with Pearson’s chi-square tests were used to assess differences 
in prophylaxis use within subgroups.
Multiple logistic regression models were developed to examine whether race/ethnicity was 
associated with the likelihood of using prophylaxis, adjusting for all other variables. 
Analyses were conducted on the entire sample and then separately on adults (20 years and 
older) and non-adults (2–19 years) to show differences in prophylaxis use between age 
groups. Since first-degree interactions of age with BMI (P=.09) and with race/ethnicity (P=.
18) were not significant, we reported the adjusted odds ratios, 95% confidence interval and P 
values from the main effect models.19
We then developed additional polynomial logistic regression models using age as a 
continuous variable to demonstrate the impact of advancing age on the probability of using 
prophylaxis among the four race/ethnicity subgroups. Figures based on these models 
illustrate the mean predicted probability of using prophylaxis with advancing age among the 
study population.
All statistical analyses were based on two-sided tests with a significance level of 0.05 and 
conducted using SAS 9.3 (SAS Institute, Cary, NC, USA).
3 | RESULTS
3.1 | Characteristics of the study population
Our sample included 2428 individuals with moderate or severe HB, aged 2–79 years (Table 
1). Half (51%) were aged 2–19, the majority of the study population were (75%) non-
Hispanic White and most individuals (90%) had either commercial or publicly funded health 
insurance. Nearly half (49%) had above-normal BMI; 23% were obese. Moderate was the 
most common haemophilic severity (56%). Nearly one-quarter (23%) of all teens aged 12–
19 practiced self-infusion, as did more than half of adults (53%) (data not shown).
3.2 | Prevalence of prophylaxis use
Proportionate use of prophylaxis was greatest among 6–11-year olds (40%), followed by 2–
5-year olds (35%) and teens 12–19 years (32%). Overall, prophylaxis was used by roughly 
one-third (35%) of those aged 2–19 years (Table 1). Individuals <20 years of age accounted 
for 73% of prophylaxis users. Among teens on a prophylactic regimen, 33% self-infused 
(data not shown).
Prophylaxis was used by less than one-fifth (14%) of all adults, and the proportion generally 
declined steadily with age, although Figure 1 reveals an increase in prophylaxis use among 
older individuals with severe HB aged 50–65 years. The proportion of younger adults (20–
39 years) on prophylaxis (17%) was twice that among adults 40 and older (8%). However, 
among self-infusers, the proportion using prophylaxis remained constant despite increasing 
age (81% among ages 20–40; 80% among those 40 years and older [data not shown]).
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Not surprisingly, prophylaxis was used more by persons with severe than moderate HB and 
by those with commercial or public insurance vs some other or no health insurance (Table 
1). Prophylaxis use was most common among Hispanic males and least common among 
non-Hispanic Whites (Figure 1). Among adults, the ability to self-infuse appeared to 
increase prophylaxis use, while overweight and obesity appeared to decrease use. 
Geographic differences in prophylaxis use fell short of the significant level (P=.053), 
although the trend suggested highest use in the West and lowest use in the Midwest.
3.3 | Association of prophylaxis use with demographic and clinical characteristics
In a multivariate analysis that included all of the studied characteristics (Table 2), several 
factors were independently associated with prophylaxis use. Patient age was strongly 
associated with prophylaxis use; younger patient groups were much more likely to use this 
therapy than adults 40 years or older.
The association of prophylaxis use varied significantly among racial/ethnic groups (P<.001); 
Hispanic ethnicity was strongly associated with increased prophylaxis use [AOR= 1.9 (1.4–
2.7), P≤.0002]. Surprisingly, children of Hispanic race/ethnicity were nearly twice as likely 
to use prophylaxis as non-Hispanic Whites.
Health insurance coverage was significantly associated with increased prophylaxis use 
[commercial insurance: AOR=6.1 (2.9–13.2), P≤.0001; publicly funded insurance: AOR=6.3 
(2.9–13.7), P≤.0001]. Those with commercial or publicly funded health insurance were six 
times more likely to use prophylaxis than those with no health insurance. BMI tended to 
interact with age group (P=.09, results not reported). Decreased use of prophylaxis was 
associated with overweight [AOR 0.5 (0.4–0.8), P=.01] and obesity [AOR 0.6 (0.4–1.0), P=.
04] among adults, but not among those <20 years. Severity was strongly associated with 
prophylaxis use: non-adults with severe haemophilia were nearly 10 times more likely to use 
prophylaxis than those with moderate disease [AOR=9.8 (7.2–13.2), P≤.0001], while adults 
with severe disease were six times more likely to treat prophylactically [AOR=5.9 (3.7–9.5), 
P≤.0001. Finally, self-infusion was significantly associated with increased prophylaxis use 
among adults [AOR=2.7 (1.7–4.2), P≤0.0001].
4 | DISCUSSION
Prophylaxis is associated with improved health and psychosocial outcomes but is costly. 
Factor concentrate accounts for most medical expenditures; a recent analysis found the 
median annual cost of factor for those with severe HA using prophylaxis to be $289 172, 
compared to $170 037 for episodic treatment.20 An understanding of utilization patterns is 
needed to effectively balance health care outcomes and resource utilization, especially as 
new therapies, such as extended half-life factor products, are introduced.
Among our sample, 24.6% of those with HB used prophylaxis, compared with 47.2% of 
those in the UDC with HA using prophylaxis.11 This difference is consistent with Canadian 
data in which 32% of those with severe HB used prophylaxis, compared to 69% of those 
with HA.14
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Evidence that HB may be clinically less severe than HA, possibly due to a milder bleeding 
phenotype, includes less frequent bleeding in those with HB, lower rates of arthroplasty and 
lower factor usage.12,13,15 The lower use of prophylaxis use among HB populations may be 
the result of less severe disease (due to more missense mutations), providers’ use of 
established haemophilia treatment practices and customs, or a combination of these 
factors.21
4.1 | Health care coverage
Health care coverage appears essential for accessing prophylactic treatment, as reported by 
Baker et al.22 The overall proportion of individuals with HB covered by some form of health 
care insurance was high (90%), but nearly twice as many adults (13%) as 2–19-year olds 
(7%) were uninsured. Because data were collected prior to implementation of the Affordable 
Care Act (ACA), some adults in our sample may have experienced greater barriers to 
prophylactic treatment than children and teens, as they were ineligible for Medicaid or 
Medicare coverage unless disabled. Additionally, lifetime limits on commercial insurance 
prior to the ACA may have restricted adults’ use of prophylaxis. Our sample includes 
individuals from the first generation to live into older age, when muscle wasting, severe 
arthropathy, and comorbidities can warrant aggressive therapy. Increasing prophylaxis use 
among 50–65-year olds with severe HB across all races/ethnicities (Figure 1) may be related 
to older individuals’ access to Medicare and thus prophylaxis.
Virtually all 2–19-year olds on prophylaxis were covered by some form of insurance (55% 
commercial insurance and 44% public insurance); only 1% had no coverage. Among adults 
using prophylaxis, 52% had commercial insurance, 43% had public insurance and 3% were 
uninsured. The fact that similar proportions of persons with publicly funded insurance (29%) 
and commercial insurance (26%) used prophylaxis suggests that insurance type is not a 
barrier to optimal care for persons treated at HTCs. Additional studies using socio-economic 
data would broaden our understanding of barriers to recommended haemophilia treatment 
among adults.
4.2 | Race and ethnicity
Our finding of significantly higher levels of prophylaxis use among Hispanic individuals 
compared to other racial/ethnic groups, provided they had insurance [AOR=1.9 (1.4, 2.7), 
P=.0002, Table 2], was unexpected. One possible explanation is the differing proportion of 
individuals with severe disease: 38% of non-Hispanic Whites, compared to 65% of African-
Americans and 65% of Hispanics. However, the larger proportion of those with severe 
haemophilia among minority groups does not explain the greater use of prophylaxis (among 
all ages) by Hispanics (47%) compared to African-Americans (30%), both of whom 
comprise a similar proportion of the overall sample population (10% and 9% respectively). 
Another explanation may be different prescribing patterns in states containing large 
proportions of African-American or Hispanic individuals; these patterns could be driven by 
more generous state funding for insurance programmes for persons with chronic illness or 
disability.
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Disparity in prophylaxis use among racial/ethnic groups was observed in both public and 
commercial coverage groups. Among those aged 2–19 with public insurance (generally 
Medicaid or Children’s Health Insurance Program (CHIP)), 63% of Hispanics used 
prophylaxis, compared to 36% of African-Americans and 29% of non-Hispanic Whites. 
Among those in the same age group covered through commercial insurance, 49% of 
Hispanics used prophylaxis, compared to 38% of African-Americans and 35% of non-
Hispanic whites. This finding indicates that HTCs provide access to optimal therapy across 
sociodemographic groups. We observed no significant association with prophylaxis among 
Hispanic adults, possibly because of the low prevalence of use among the overall adult 
population (14%), and insufficient sample size (n=67), which may reflect the fact that some 
adult Hispanics are unable to access insurance coverage (and therefore prophylaxis) due to 
lack of legal US residency.
4.3 | Increased BMI
Although obesity was significantly associated with lower prophylaxis use only among 
adults, young persons were disproportionally affected by obesity (19% of 2–11-year olds 
and 16% of teens, compared to 11% of adults). Among 2–11-year olds, obesity was more 
prevalent than overweight; among those with obesity, 14% had morbid obesity. National 
Health and Nutrition Examination Survey data collected in 2009–2010 indicate that although 
the prevalence of obesity among the general U.S. population has stabilized among most age 
groups, it continues to rise among male adolescents.23
An obesity prevalence approaching 20% among those most likely to use prophylaxis (2–11-
year olds) has significant economic implications. Prophylactic regimens can use up to three 
times more factor concentrate than episodic treatment.24,25 Dosing is based on actual, not 
ideal, body weight; consequently, a prophylactic regimen for an obese or overweight child is 
more costly than for one of normal weight. Using patient data from one HTC, prophylactic 
factor costs for 19 overweight or obese 2–19-year olds with severe HA or HB not using a 
bypassing agent would cost over $1 million per year (ie roughly $50 000 per person on 
average) more than if they had a normal body weight, not taking into account 340B program 
subsidies.26 In our sample, 163 overweight or obese 2–19-year olds were treated 
prophylactically, using an estimated $8 million dollars more in factor costs than if they were 
of normal weight. Public funds covered 29% of individuals using prophylaxis. In an era of 
constrained healthcare resources, monitoring the BMI of young males at risk for obesity and 
initiating preventive measures must become a priority for HTCs.
4.4 | Study limitations
Some limitations should be noted when interpreting our results. Data were collected prior to 
the introduction of extended half-life factor IX products; widespread adoption of these may 
alter future patterns of prophylaxis use by making prophylactic treatment more accessible 
for patients. Our sample was derived from volunteer participants receiving care through 
federally funded HTCs. The prevalence of HB in our study population (25%) is slightly 
higher than some published estimates, possibly due to the greater number of blood-borne 
virus-related deaths among persons with severe HA during the past 25 years..27 We also note 
that the prevalence of individuals with severe HB (45%) is higher than that reported by a 
Ullman et al. Page 7
Haemophilia. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Canadian survey of HTCs (32%).14 Data collected for the UDC surveillance project were 
not confirmed with pharmacy or home care records. BMI does not distinguish between fat 
mass and fat-free mass; however, studies demonstrate that the association between BMI and 
body fat is strong among those with higher BMI levels.28 Small sample size may be an issue 
in analyses of subgroups stratified simultaneously by numerous variables, such as Hispanic 
persons >40 years using prophylaxis.
5 | CONCLUSION
We found that (i) the overall prevalence of prophylaxis use among males with moderate and 
severe HB was 25% among individuals with moderate disease and 45% among those with 
severe disease; and (ii) age and severity are strongly associated with HB prophylaxis use. 
Prophylactic treatment was associated with young age: 6–11-year olds were the most likely 
to use prophylaxis, while adults 40 years and older were the least likely to do so. 
Prophylaxis was used by nearly six times as many individuals with severe disease as those 
with moderate haemophilia.
Health care coverage was vital: only eight individuals (3 aged 2–19 and 5 adults) without 
insurance used prophylaxis; type of coverage (public vs commercial) did not appear to 
influence access. Increased prophylaxis use was associated with younger age and Hispanic 
race/ethnicity, while above-normal BMI in adults was associated with decreased prophylaxis 
use. Future analyses directly comparing the use of prophylaxis among US HA and HB 
populations, racial/ethnic groups and geographic regions will increase our understanding of 
evolving haemophilia treatment patterns and implications for the allocation of haemophilia 
treatment resources.
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FIGURE 1. 
Predicted probability of prophylaxis use in males with moderate to severe haemophilia B by 
race/ethnicity
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TABLE 1
Prevalence of prophylaxis use by patient characteristics among males with moderate to severe haemophilia B
Characteristic Totala N=2428, No. (%) Prophylaxis useb N=598, No. (%)
Episodic treatment N=1830, No. 
(%) P valuec
Age
All youth (2–19 y) 1246 (51) 437 (35) 809 (65) <.0001
All adults (20+ y) 1182 (49) 161 (14) 1021 (86)
 2–5 y 240 (10) 84 (35) 156 (65) <.0001
 6–11 y 399 (16) 160 (40) 239 (60)
 12–19 y 607 (25) 193 (32) 414 (68)
 20–40 y 725 (30) 126 (17) 599 (83)
 40+ y 457 (19) 35 (8) 422 (92)
Race/ethnicity
 Non-Hispanic White 1810 (75) 355 (20) 1455 (80) <.0001
 African-American 230 (9) 70 (30) 160 (70)
 Hispanic 241 (10) 114 (47) 127 (53)
 Other 147 (6) 59 (40) 88 (60)
Health insurance
 Commercial 1269 (52) 326 (26) 943 (74) <.0001
 Publicly funded 888 (37) 261 (29) 627 (71)
 Other/unknown 31 (1) 3 (10) 28 (90)
 No insurance 240 (10) 8 (3) 232 (97)
BMI status
 Normal weight or less 1233 (51) 352 (29) 881 (71) <.0001
 Overweight 640 (26) 128 (23) 427 (77)
 Obese 555 (23) 118 (18) 522 (82)
Severity
 Moderate 1349 (56) 109 (8) 1240 (92) <.0001
 Severe 1079 (44) 489 (45) 590 (55)
Self-infusion
 Yes 772 (32) 198 (26) 574 (74) .45
 No 1656 (68) 400 (24) 1256 (76)
Census bureau regionsd
 Midwest 877 (36) 146 (17) 731 (83) <.0001
 Northeast 494 (20) 133 (27) 361 (73)
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Characteristic Totala N=2428, No. (%) Prophylaxis useb N=598, No. (%)
Episodic treatment N=1830, No. 
(%) P valuec
 South 590 (24) 162 (27) 428 (73)
 West 467 (19) 157 (34) 310 (66)
a
Distribution of demographic and clinical characteristics among males with Haemophilia B, row %.
b
Prevalence of prophylaxis use, column %.
cP value calculated using Chi-squared test.
d
Percentages in the total column sum to 99%; the remaining 1% is distributed nearly evenly among the four regional categories.
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